Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
Open Access
- 14 May 2020
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 9 (2) , 443-457
Abstract
Introduction In clinical trials of alemtuzumab, autoimmune thyroid adverse events (AEs) were frequent. Here, we assess the impact of thyroid AEs on health-related quality of life (HRQL) in alemtuzumab-treated patients with relapsing-remitting multiple sclerosis (RRMS). Methods In phase 3 CARE-MS I (NCT00530348) and II (NCT00548405) trials, patients with RRMS were administered alemtuzumab 12 mg/day on 5 consecutive days at baseline and on 3 consecutive days 12 months later. Patients could participate in an extension study (NCT00930553) through year 6. HRQL was assessed at baseline and annually using the Functional Assessment of Multiple Sclerosis (FAMS), EuroQoL-5 Dimension Visual Analog Scale (EQ-5D VAS), and 36-Item Short-Form Survey (SF-36) questionnaires. Outcomes were analyzed in patients with or without thyroid AEs (nonserious or serious). A subset of patients with thyroid AEs was analyzed to assess HRQL before and during the onset of thyroid AEs. Results A total of 811 CARE-MS patients were treated with alemtuzumab. Of these, 342 (42%) patients experienced thyroid AEs over 6 years; serious thyroid AEs occurred in 44 (5%) patients. At year 6, HRQL outcomes generally remained slightly improved or similar to core study baseline in alemtuzumab-treated patients with or without thyroid AEs: FAMS (least-squares mean change from baseline without thyroid AEs, 0.7; with nonserious thyroid AEs, 5.1; with serious thyroid AEs, − 5.3), EQ-5D VAS (2.0; 3.0; − 6.8), SF-36 mental component summary (MCS [0.6; 1.6; − 2.8]), SF-36 physical component summary (PCS [0.8; 1.0; 1.1]). Over 6 years, 63–82% of patients in each group had improved/stable SF-36 MCS and PCS scores. Among patients with thyroid AE onset in year 3 (peak incidence), there were minimal differences between HRQL outcomes before onset (year 2) and after onset (year 3). Conclusion Autoimmune thyroid AEs (serious and nonserious) had minimal impact on HRQL in alemtuzumab-treated patients. These data may aid therapeutic decisions in patients with relapsing MS.Keywords
Funding Information
- Sanofi
- Bayer HealthCare Pharmaceuticals
This publication has 24 references indexed in Scilit:
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialThe Lancet, 2012
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialThe Lancet, 2012
- Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosisJournal of the Neurological Sciences, 2011
- Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies.2011
- Health‐related quality of life in multiple sclerosis: effects of natalizumabAnnals of Neurology, 2007
- Impaired health-related quality of life in Graves' disease. A prospective studyEuropean Journal of Endocrinology, 2004
- Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profilesJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Validation of the Functional Assessment of Multiple Sclerosis quality of life instrumentNeurology, 1996
- EuroQol: the current state of playHealth Policy, 1996
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992